Replies to post #2069 on Revance Therapeutics Inc (RVNC)

[jmkobers]

The company's vision for the toxin landscape after RVNC's approval is that most practices will have a long acting toxin (Daxi) and a basket of others, including Botox, that are similar acting and shorter lasting, but price will vary on them based on brand.

So, just another widget for the shorter lasting toxin bin, and just valued at 3 billion? Huh

Valued 1.8 worth 5